Oronsky B, Ma PC, Morgensztern D, Carter CA (2017) Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia 19:991–1002

Article  CAS  PubMed  PubMed Central  Google Scholar 

White BE, Rous B, Chandrakumaran K et al (2022) Incidence and survival of neuroendocrine neoplasia in England 1995–2018: a retrospective, population-based study. Lancet Reg Health Eur 23:100510

Article  PubMed  PubMed Central  Google Scholar 

Yoo C, Oh CR, Kim ST et al (2021) Systemic treatment of advanced gastroenteropancreatic neuroendocrine tumors in Korea: literature review and expert opinion. Cancer Res Treat 53:291–300

Article  CAS  PubMed  Google Scholar 

Hermans BCM, de Vos-Geelen J, Derks JL et al (2021) Unique metastatic patterns in neuroendocrine neoplasms of different primary origin. Neuroendocrinology 111:1111–1120

Article  CAS  PubMed  Google Scholar 

Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K (2016) The epidemiology of metastases in neuroendocrine tumors. Int J Cancer 139:2679–2686

Article  PubMed  Google Scholar 

Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124–2130

Article  CAS  PubMed  Google Scholar 

Kwekkeboom DJ, Teunissen JJ, Bakker WH et al (2005) Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23:2754–2762

Article  CAS  PubMed  Google Scholar 

Camus B, Cottereau AS, Palmieri LJ et al (2021) Indications of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic and pulmonary neuroendocrine tumors: an updated review. J Clin Med 10:1267

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shamim SA, Arora G, Kumar N et al (2023) 68Ga-DOTANOC PET/CT for screening and surveillance of Von Hippel-Lindau (VHL) disease. Nucl Med Mol Imaging 57:235–242

Article  CAS  PubMed  PubMed Central  Google Scholar 

National Comprehensive Cancer Network (2023) Neuroendocrine and adrenal tumors (Version 1.2023). Available via https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed 5 Mar 2024

Kratochwil C, Stefanova M, Mavriopoulou E et al (2015) SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol 17:313–318

Article  CAS  PubMed  Google Scholar 

Ortega C, Wong RKS, Schaefferkoetter J et al (2021) Quantitative 68Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177Lu-DOTATATE. J Nucl Med 62:1406–1414

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharma R, Wang WM, Yusuf S et al (2019) 68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. Radiother Oncol 141:108–115

Article  CAS  PubMed  Google Scholar 

Trautwein NF, Schwenck J, Jacoby J et al (2023) Long-term prognostic factors for PRRT in neuroendocrine tumors. Front Med 10:1169970

Article  Google Scholar 

Ohlendorf F, Henkenberens C, Brunkhorst T et al (2022) Volumetric 68Ga-DOTA-TATE PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with metastatic gastroenteropancreatic neuroendocrine tumors. Q J Nucl Med Mol Imaging 66:361–371

Article  PubMed  Google Scholar 

Durmo R, Filice A, Fioroni F et al (2022) Predictive and prognostic role of pre-therapy and interim 68Ga-DOTATOC PET/CT parameters in metastatic advanced neuroendocrine tumor patients treated with PRRT. Cancers 14:592

Article  PubMed  PubMed Central  Google Scholar 

Ebbers SC, Heimgartner M, Barentsz MW et al (2021) Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study. Eur J Hybrid Imaging 5:22

Article  PubMed  PubMed Central  Google Scholar 

Mileva M, Marin G, Levillain H et al (2024) Prediction of 177Lu-DOTATATE PRRT outcome using multimodality imaging in patients with gastroenteropancreatic neuroendocrine tumors: results from a prospective phase II LUMEN study. J Nucl Med 65:236–244

Article  CAS  PubMed  Google Scholar 

Urso L, Castello A, Treglia G et al (2023) Relevance of volumetric parameters applied to [68Ga]Ga-DOTATOC PET/CT in NET patients treated with PRRT. Diagnostics 13:606

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shin Y, Moon BH, Ryoo BY et al (2024) Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea. Target Oncol 19:41–49

Kim YI, Yoo C, Oh SJ et al (2020) Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. EJNMMI Res 10:63

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

Article  CAS  PubMed  Google Scholar 

Strosberg J, El-Haddad G, Wolin E et al (2017) Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 376:125–135

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gallicchio R, Giordano A, Milella M et al (2023) Ga-68-edotreotide positron emission tomography/computed tomography somatostatin receptors tumor volume predicts outcome in patients with primary gastroenteropancreatic neuroendocrine tumors. Cancer Control 30:10732748231152328

Article  PubMed  PubMed Central  Google Scholar 

Gabriel M, Oberauer A, Dobrozemsky G et al (2009) 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med 50:1427–1434

Article  CAS  PubMed  Google Scholar 

Soydal Ç, Peker A, Özkan E, Küçük ÖN, Kir MK (2016) The role of baseline Ga-68 DOTATATE positron emission tomography/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with Lu-177 DOTATATE. Turk J Med Sci 46:409–413

Article  CAS  PubMed  Google Scholar 

Pauwels E, Dekervel J, Verslype C et al (2022) [68Ga]Ga-DOTATATE-avid tumor volume, uptake and inflammation-based index correlate with survival in neuroendocrine tumor patients treated with [177Lu]Lu-DOTATATE PRRT. Am J Nucl Med Mol Imaging 12:152–162

CAS  PubMed  PubMed Central  Google Scholar 

Pavel M, Baudin E, Couvelard A et al (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95:157–176

Article  CAS  PubMed  Google Scholar 

Katal S, Eibschutz LS, Saboury B et al (2022) Advantages and applications of total-body PET scanning. Diagnostics 12:426

Article  PubMed  PubMed Central  Google Scholar 

Filippi L, Dimitrakopoulou-Strauss A, Evangelista L et al (2022) Long axial field-of-view PET/CT devices: are we ready for the technological revolution? Expert Rev Med Devices 19:739–743

Article  CAS  PubMed  Google Scholar